AGL
NEUTRALANGLE plc Announces Novel Discoveries into the Biology of Cancer
The medical diagnostics company reports on new peer-reviewed publications highlighting the use of its Parsortix system in advancing cancer research.
ANGLE
7.90GBX
8.97%
Market Cap
25.48M
Volume
788.52k
58% of avg
P/E Ratio
-0.02
EPS (TTM)
-3.65
Beta
0.08
Day Range
6.50p - 7.90p
52 Week Range
6.50p7.90p17.44p
7.90p
Upcoming Events
30 June 2025
Annual General Meeting
Early Q1 2026
End of current cash runway
High Impact Event
AGL
NEUTRALANGLE plc Provides Annual Report and AGM Notice
The healthcare diagnostics company has posted its annual report and notice of AGM for shareholders.
AGL
NEUTRALANGLE plc Announces Board Changes
The healthcare diagnostics company announces changes to its board of directors, with a non-executive director retiring and another resigning.
AGL
NEUTRALANGLE plc Reports Mixed Results: Revenue Up 31%, But Funding Concerns Persist
The medical diagnostics firm reported a 31% revenue increase but faces ongoing losses and funding challenges. Despite progress in pharma contracts, market turbulence impacts current trading.
AGL
GOODANGLE plc to Release Preliminary Results
The medical diagnostic company will be releasing its preliminary results for the previous year, providing investors with an update on the business's performance.
AGL
NEUTRALANGLE Presents New Data Supporting HER2 Assay Development
The medical diagnostics company presents new data supporting the development of its HER2 assay kit, which aims to provide a minimally invasive way to assess HER2 status in cancer patients.
AGL
NEUTRALANGLE plc Issues LTIP and Share Options to Executives and Staff
The healthcare company has granted options to executives and staff under its long-term incentive plan and share option schemes.
AGL
NEUTRALANGLE plc Completes Assay Development for AstraZeneca and Eisai Phase 2 Study
The medical diagnostics company has successfully completed assay development projects for AstraZeneca and reported results from a Phase 2 pilot study for Eisai, demonstrating the capabilities of its Parsortix system.
AGL
GOODANGLE's Parsortix System Enables Groundbreaking Cancer Metastasis Research
The medical diagnostic company's Parsortix system enabled pioneering research on the role of CTC:B cell clusters in driving cancer metastasis, which could lead to new treatment options.
AGL
GOODANGLE Announces Successful Dual CTC-DNA and ctDNA Analysis Using Illumina Platform
The medical diagnostics company announces successful results for its dual circulating tumour cell and circulating tumour DNA analysis workflow using Illumina's technology, which could enhance the value of its Parsortix system.